NetScientific portfolio company PDS Biotechnology to advance lead candidate PDS0101 with term loan

Frank Bedu-Addo, president and CEO of PDS Biotechnology Corporation (NASDAQ:PDSB), a NetScientific PLC (AIM:NSCI) portfolio company, tells Proactive’s Stephen Gunnion that a recent US$35mln debt financing agreement provides the financial resources necessary to advance the company’s clinical pipeline.

Together with cash on hand, Bedu-Addo said the term loan will be used to support the ongoing clinical development of lead candidate PDS0101, which targets cancers associated with the human papillomavirus, as well as other product candidates.

PDS is anticipating a number of important milestones across its oncology and infectious disease programmes, he added.

#ProactiveInvestors #NetScientific #PDSBiotechnology #cancer #AIM #Nasdaq

You might like

© 2022 The Latest StockMarket News and Interviews